Literature DB >> 6601805

Role of carbohydrate in multimeric structure of factor VIII/von Willebrand factor protein.

H R Gralnick, S B Williams, M E Rick.   

Abstract

The carbohydrate moiety of the factor VIII/von Willebrand (vW) factor protein is important in the expression of vW factor activity and the intravascular survival of the protein. Studies of normal human factor VIII/vW factor protein indicate that there is a requirement of a full complement of penultimate galactose for the maintenance of a normal multimeric structure. Release of penultimate galactose by beta-galactosidase or modification by galactose oxidase results in loss of the largest molecular weight multimers and increased numbers of intermediate and smaller multimers. In contrast, terminal galactose on the factor VIII/vW factor protein does not appear to play a significant role in the maintenance of the multimer organization. The abnormalities in multimeric structure and molecular size were demonstrated by NaDodSO4/polyacrylamide/agarose gel electrophoresis, NaDodSO4/glyoxyl-agarose electrophoresis, and sucrose density ultracentrifugation. These studies indicate that the penultimate galactose plays a role in the maintenance of the largest multimers of the factor VIII/vW factor protein. This may explain why, in some patients with variant forms of vW disease, a carbohydrate abnormality also may affect the multimeric structure of the plasma factor VIII/vW factor protein.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6601805      PMCID: PMC393910          DOI: 10.1073/pnas.80.9.2771

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  15 in total

1.  Disulfide bonds and the quaternary structure of factor VIII/von Willebrand factor.

Authors:  R B Counts; S L Paskell; S K Elgee
Journal:  J Clin Invest       Date:  1978-09       Impact factor: 14.808

2.  Factor VIII/von Willebrand factor protein. Galactose a cryptic determinant of von Willebrand factor activity.

Authors:  H R Gralnick
Journal:  J Clin Invest       Date:  1978-08       Impact factor: 14.808

3.  Factor VIII/von Willebrand protein. Modification of its carbohydrate causes reduced binding to platelets.

Authors:  K J Kao; S V Pizzo; P A McKee
Journal:  J Biol Chem       Date:  1980-11-10       Impact factor: 5.157

4.  Variant von Willebrand's disease: characterization of two subtypes by analysis of multimeric composition of factor VIII/von Willebrand factor in plasma and platelets.

Authors:  Z M Ruggeri; T S Zimmerman
Journal:  J Clin Invest       Date:  1980-06       Impact factor: 14.808

5.  Effect of multimeric structure of the factor VIII/von Willebrand factor protein on binding to platelets.

Authors:  H R Gralnick; S B Williams; D K Morisato
Journal:  Blood       Date:  1981-08       Impact factor: 22.113

6.  Studies of the human factor VIII/von Willebrand factor protein. III. Qualitative defects in von Willebrand's disease.

Authors:  H R Gralnick; B S Coller; Y Sultan
Journal:  J Clin Invest       Date:  1975-10       Impact factor: 14.808

7.  Studies on factor VIII-related protein. II. Estimation of molecular size differences between factor VIII oligomers.

Authors:  B A Perret; M Furlan; E A Beck
Journal:  Biochim Biophys Acta       Date:  1979-05-23

8.  The subunit structure of normal and hemophilic factor VIII.

Authors:  G A Shapiro; J C Andersen; S V Pizzo; P A McKee
Journal:  J Clin Invest       Date:  1973-09       Impact factor: 14.808

9.  Properties of human asialo-factor VIII. A ristocetin-independent platelet-aggregating agent.

Authors:  L De Marco; S S Shapiro
Journal:  J Clin Invest       Date:  1981-08       Impact factor: 14.808

10.  Factor VIII-related protein circulates in normal human plasma as high molecular weight multimers.

Authors:  L W Hoyer; J R Shainoff
Journal:  Blood       Date:  1980-06       Impact factor: 22.113

View more
  6 in total

1.  Optimization of cell culture conditions for production of biologically active proteins.

Authors:  S Hosoi; H Miyaji; M Satoh; T Kurimoto; A Mihara; N Fujiyoshi; S Itoh; S Sato
Journal:  Cytotechnology       Date:  1991-01       Impact factor: 2.058

2.  Asialo von Willebrand factor interactions with platelets. Interdependence of glycoproteins Ib and IIb/IIIa for binding and aggregation.

Authors:  H R Grainick; S B Williams; B S Coller
Journal:  J Clin Invest       Date:  1985-01       Impact factor: 14.808

3.  Primary structure of the major O-glycosidically linked carbohydrate unit of human von Willebrand factor.

Authors:  B Samor; J C Michalski; C Mazurier; M Goudemand; P De Waard; J F Vliegenthart; G Strecker; J Montreuil
Journal:  Glycoconj J       Date:  1989       Impact factor: 2.916

4.  Carbohydrate moiety of von Willebrand factor is not necessary for maintaining multimeric structure and ristocetin cofactor activity but protects from proteolytic degradation.

Authors:  A B Federici; J H Elder; L De Marco; Z M Ruggeri; T S Zimmerman
Journal:  J Clin Invest       Date:  1984-12       Impact factor: 14.808

5.  Stable production of recombinant pro-urokinase by human lymphoblastoid Namalwa KJM-1 cells: host-cell dependency of the expressed-protein stability.

Authors:  M Satoh; S Hosoi; H Miyaji; S Itoh; S Sato
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

6.  Expression of human beta-interferon in Namalwa KJM-1 which was adapted to serum-free medium.

Authors:  H Miyaji; T Mizukami; S Hosoi; S Sato; N Fujiyoshi; S Itoh
Journal:  Cytotechnology       Date:  1990-03       Impact factor: 2.058

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.